Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CROMOLYN NASAL SPRAY | 2% | SOLUTION SPRAY | Actual shortage | 2017-08-13 | 2017-10-05 | 19051 |
| APO-CROMOLYN STERULES | 1% | SOLUTION | Actual shortage | 2017-08-13 | 2017-10-05 | 19054 |
| APO-CYCLOBENZAPRINE | 10MG | TABLET | Resolved | 2018-03-05 | 2018-04-14 | 41844 |
| APO-CYCLOBENZAPRINE | 10MG | TABLET | Resolved | 2024-05-03 | 2024-05-17 | 227091 |
| APO-CYCLOBENZAPRINE | 10MG | TABLET | Resolved | 2024-07-04 | 2024-09-27 | 232292 |
| APO-CYCLOSPORINE ORAL SOLUTION | 100MG | SOLUTION | Resolved | 2017-03-10 | 2018-09-09 | 241 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2022-11-20 | 2023-01-20 | 175318 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2023-02-23 | 2023-03-23 | 185492 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2023-04-14 | 2023-06-08 | 189659 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2019-06-26 | 2022-10-07 | 87509 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2020-08-19 | 2021-01-26 | 122473 |
| APO-DABIGATRAN | 75MG | CAPSULE | Resolved | 2024-06-13 | 2024-07-19 | 230477 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2024-06-14 | 2024-09-20 | 230558 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-06-14 | 2024-09-20 | 230561 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2024-07-12 | 2024-07-19 | 232842 |
| APO-DABIGATRAN | 150MG | CAPSULE | Actual shortage | 2024-10-24 | 2024-10-24 | 241059 |
| APO-DABIGATRAN | 110MG | CAPSULE | Actual shortage | 2024-11-15 | 2024-11-15 | 243170 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-12-05 | 2025-01-24 | 244888 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2024-02-09 | 2024-02-23 | 219149 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-02-09 | 2024-02-23 | 219152 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |